BTG and Mirada, a medical imaging software company, have announced an important collaboration to develop dosimetry software solutions to optimise radioembolization therapy with TheraSphere.
Both companies are working together to provide a more personalised approach to radioembolization for liver cancer patients, through easy-to-use and bespoke software that helps physicians plan the delivery of a specific radiation dose based on an individual patient’s need.
TheraSphere 90Y glass microspheres are specifically engineered to deliver high doses of radiation to liver tumours while sparing normal tissue. In the European Union, TheraSphere is CE marked for the treatment of hepatic neoplasia. In the USA, TheraSphere is FDA approved under a humanitarian device exemption for the treatment of hepatocellular carcinoma (HCC).
Peter Pattison, BTG general manager, interventional oncology, commercial operations, commented: “We are committed to providing patients and healthcare providers with value beyond just our products to improve outcomes for patients and ensure that our therapies are tailored to individual patient needs.”
Matthieu Leclerc-Chalvet, Mirada Medical, managing director, said: “Our goal is to provide intuitive software that facilitates the clinician’s use of multimodal images to plan radioembolization with the ultimate aim of leading to better patient outcomes. The collaboration with BTG leverages our image processing expertise and highlights the importance of imaging for planning treatments.”
The companies plan to make the software available in 2016.
